Angiogenesis最新文献

{"title":"People with a connective tissue disorder may be especially vulnerable to the endothelial damage that characterizes long COVID due to the fragility of their vasculature and slow wound healing","authors":"Jeffrey Lubell","doi":"10.1007/s10456-024-09908-w","DOIUrl":"10.1007/s10456-024-09908-w","url":null,"abstract":"<div><p>A growing body of evidence documents the central role that endothelial damage plays in the pathophysiology of long COVID. But it remains unclear why only certain people get Long COVID and why recovery times are so long for many affected individuals. One potential explanation is that some forms of long COVID are experienced disproportionately by people with a connective tissue disorder who are more vulnerable than others to incurring serious damage to the endothelium and the vascular extracellular matrix from the inflammatory processes triggered by COVID-19 and much slower to heal. Further research is needed to explore this hypothesis.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 2","pages":"123 - 124"},"PeriodicalIF":9.2,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors","authors":"T. Al Tabosh,&nbsp;H. Liu,&nbsp;D. Koça,&nbsp;M. Al Tarrass,&nbsp;L. Tu,&nbsp;S. Giraud,&nbsp;L. Delagrange,&nbsp;M. Beaudoin,&nbsp;S. Rivière,&nbsp;V. Grobost,&nbsp;M. Rondeau-Lutz,&nbsp;O. Dupuis,&nbsp;N. Ricard,&nbsp;E. Tillet,&nbsp;P. Machillot,&nbsp;A. Salomon,&nbsp;C. Picart,&nbsp;C. Battail,&nbsp;S. Dupuis-Girod,&nbsp;C. Guignabert,&nbsp;A. Desroches-Castan,&nbsp;S. Bailly","doi":"10.1007/s10456-023-09902-8","DOIUrl":"10.1007/s10456-023-09902-8","url":null,"abstract":"<div><p>Heterozygous activin receptor-like kinase 1 (<i>ALK1</i>) mutations are associated with two vascular diseases: hereditary hemorrhagic telangiectasia (HHT) and more rarely pulmonary arterial hypertension (PAH). Here, we aimed to understand the impact of <i>ALK1</i> mutations on BMP9 and BMP10 transcriptomic responses in endothelial cells. Endothelial colony-forming cells (ECFCs) and microvascular endothelial cells (HMVECs) carrying loss of function <i>ALK1</i> mutations were isolated from newborn HHT and adult PAH donors, respectively. RNA-sequencing was performed on each type of cells compared to controls following an 18 h stimulation with BMP9 or BMP10. In control ECFCs, BMP9 and BMP10 stimulations induced similar transcriptomic responses with around 800 differentially expressed genes (DEGs). <i>ALK1</i>-mutated ECFCs unexpectedly revealed highly similar transcriptomic profiles to controls, both at the baseline and upon stimulation, and normal activation of Smad1/5 that could not be explained by a compensation in cell-surface ALK1 level. Conversely, PAH HMVECs revealed strong transcriptional dysregulations compared to controls with &gt; 1200 DEGs at the baseline. Consequently, because our study involved two variables, ALK1 genotype and BMP stimulation, we performed two-factor differential expression analysis and identified 44 BMP9-dysregulated genes in mutated HMVECs, but none in ECFCs. Yet, the impaired regulation of at least one hit, namely lunatic fringe (<i>LFNG</i>), was validated by RT-qPCR in three different <i>ALK1</i>-mutated endothelial models. In conclusion, <i>ALK1</i> heterozygosity only modified the BMP9/BMP10 regulation of few genes, including <i>LFNG</i> involved in NOTCH signaling. Future studies will uncover whether dysregulations in such hits are enough to promote HHT/PAH pathogenesis, making them potential therapeutic targets, or if second hits are necessary.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 2","pages":"211 - 227"},"PeriodicalIF":9.2,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11021321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of endothelial PDGFB in arterio-venous malformations pathogenesis","authors":"Yanzhu Lin,&nbsp;Johannes Gahn,&nbsp;Kuheli Banerjee,&nbsp;Gergana Dobreva,&nbsp;Mahak Singhal,&nbsp;Alexandre Dubrac,&nbsp;Roxana Ola","doi":"10.1007/s10456-023-09900-w","DOIUrl":"10.1007/s10456-023-09900-w","url":null,"abstract":"<div><p>Arterial-venous malformations (AVMs) are direct connections between arteries and veins without an intervening capillary bed. Either familial inherited or sporadically occurring, localized pericytes (PCs) drop is among the AVMs’ hallmarks. Whether impaired PC coverage triggers AVMs or it is a secondary event is unclear. Here we evaluated the role of the master regulator of PC recruitment, Platelet derived growth factor B (PDGFB) in AVM pathogenesis. Using tamoxifen-inducible deletion of <i>Pdgfb</i> in endothelial cells (ECs), we show that disruption of EC <i>Pdgfb</i>-mediated PC recruitment and maintenance leads to capillary enlargement and organotypic AVM-like structures. These vascular lesions contain non-proliferative hyperplastic, hypertrophic and miss-oriented capillary ECs with an altered capillary EC fate identity. Mechanistically, we propose that PDGFB maintains capillary EC size and caliber to limit hemodynamic changes, thus restricting expression of Krüppel like factor 4 and activation of Bone morphogenic protein, Transforming growth factor β and NOTCH signaling in ECs. Furthermore, our study emphasizes that inducing or activating PDGFB signaling may be a viable therapeutic approach for treating vascular malformations.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 2","pages":"193 - 209"},"PeriodicalIF":9.2,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-023-09900-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138559936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Von Willebrand factor: a consistent biomarker predicting in-hospital mortality across different waves of the COVID-19 pandemic","authors":"David M. Smadja,&nbsp;Anne-Sophie Jannot,&nbsp;Aurélien Philippe,&nbsp;Estelle Lu,&nbsp;Jeanne Rancic,&nbsp;Olivier Sanchez,&nbsp;Richard Chocron,&nbsp;Nicolas Gendron,&nbsp;Jean-Luc Diehl","doi":"10.1007/s10456-023-09901-9","DOIUrl":"10.1007/s10456-023-09901-9","url":null,"abstract":"","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 1","pages":"1 - 4"},"PeriodicalIF":9.2,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality imaging reveals angiogenic evolution in vivo during calvarial bone defect healing","authors":"Yunke Ren,&nbsp;Xinying Chu,&nbsp;Janaka Senarathna,&nbsp;Akanksha Bhargava,&nbsp;Warren L. Grayson,&nbsp;Arvind P. Pathak","doi":"10.1007/s10456-023-09899-0","DOIUrl":"10.1007/s10456-023-09899-0","url":null,"abstract":"<div><p>The healing of calvarial bone defects is a pressing clinical problem that involves the dynamic interplay between angiogenesis and osteogenesis within the osteogenic niche. Although structural and functional vascular remodeling (i.e., angiogenic evolution) in the osteogenic niche is a crucial modulator of oxygenation, inflammatory and bone precursor cells, most clinical and pre-clinical investigations have been limited to characterizing structural changes in the vasculature and bone. Therefore, we developed a new multimodality imaging approach that for the first time enabled the longitudinal (i.e., over four weeks) and dynamic characterization of multiple in vivo functional parameters in the remodeled vasculature and its effects on de novo osteogenesis, in a preclinical calvarial defect model. We employed multi-wavelength intrinsic optical signal (IOS) imaging to assess microvascular remodeling, intravascular oxygenation (SO₂), and osteogenesis; laser speckle contrast (LSC) imaging to assess concomitant changes in blood flow and vascular maturity; and micro-computed tomography (μCT) to validate volumetric changes in calvarial bone. We found that angiogenic evolution was tightly coupled with calvarial bone regeneration and corresponded to distinct phases of bone healing, such as injury, hematoma formation, revascularization, and remodeling. The first three phases occurred during the initial two weeks of bone healing and were characterized by significant in vivo changes in vascular morphology, blood flow, oxygenation, and maturity. Overall, angiogenic evolution preceded osteogenesis, which only plateaued toward the end of bone healing (i.e., four weeks). Collectively, these data indicate the crucial role of angiogenic evolution in osteogenesis. We believe that such multimodality imaging approaches have the potential to inform the design of more efficacious tissue-engineering calvarial defect treatments.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 1","pages":"105 - 119"},"PeriodicalIF":9.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells","authors":"Andrei Turtoi,&nbsp;Denis Mottet,&nbsp;Nicolas Matheus,&nbsp;Bruno Dumont,&nbsp;Paul Peixoto,&nbsp;Vincent Hennequière,&nbsp;Christophe Deroanne,&nbsp;Alain Colige,&nbsp;Edwin De Pauw,&nbsp;Akeila Bellahcène,&nbsp;Vincent Castronovo","doi":"10.1007/s10456-023-09898-1","DOIUrl":"10.1007/s10456-023-09898-1","url":null,"abstract":"","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 1","pages":"121 - 122"},"PeriodicalIF":9.2,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71477258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Notch ligands are biomarkers of anti-TNF response in RA patients","authors":"Stephanie R. Zack,&nbsp;Anja Meyer,&nbsp;Brian Zanotti,&nbsp;Michael V. Volin,&nbsp;Sania Deen,&nbsp;Neha Satoeya,&nbsp;Nadera Sweiss,&nbsp;Myles J. Lewis,&nbsp;Costantino Pitzalis,&nbsp;Jan K. Kitajewski,&nbsp;Shiva Shahrara","doi":"10.1007/s10456-023-09897-2","DOIUrl":"10.1007/s10456-023-09897-2","url":null,"abstract":"<div><p>Notch and its ligands play a critical role in rheumatoid arthritis (RA) pathogenesis. Hence, studies were conducted to delineate the functional significance of the Notch pathway in RA synovial tissue (ST) cells and the influence of RA therapies on their expression. Morphological studies reveal that JAG1, DLL4, and Notch1 are highly enriched in RA ST lining and sublining CD68⁺CD14⁺ MΦs. JAG1 and DLL4 transcription is jointly upregulated in RA MΦs reprogrammed by TLR4/5 ligation and TNF, whereas Syntenin-1 exposure expands JAG1, DLL4, and Notch1 expression levels in these cells. Single-cell RNA-seq data exhibit that JAG1 and Notch3 are overexpressed on all fibroblast-like synoviocyte (FLS) subpopulations, in parallel, JAG2, DLL1, and Notch1 expression levels are modest on RA FLS and are predominately potentiated by TLR4 ligation. Intriguingly, JAG1, DLL1/4, and Notch1/3 are presented on RA endothelial cells, and their expression is mutually reconfigured by TLR4/5 ligation in the endothelium. Synovial JAG1/JAG2/DLL1 or Notch1/3 transcriptomes were unchanged in patients who received disease-modifying anti-rheumatic drugs (DMARDs) or IL-6R Ab therapy regardless of disease activity score. Uniquely, RA MΦs and endothelial cells rewired by IL-6 displayed DLL4 transcriptional upregulation, and IL-6R antibody treatment disrupted RA ST DLL4 transcription in good responders compared to non-responders or moderate responders. Nevertheless, the JAG1/JAG2/DLL1/DLL4 transcriptome was diminished in anti-TNF good responders with myeloid pathotype and was unaltered in the fibroid pathotype except for DLL4. Taken together, our findings suggest that RA myeloid Notch ligands can serve as markers for anti-TNF responsiveness and trans-activate Notch receptors expressed on RA FLS and/or endothelial cells.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 2","pages":"273 - 283"},"PeriodicalIF":9.2,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41105451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the microenvironment in the treatment of arteriovenous malformations","authors":"Caroline T. Seebauer,&nbsp;Benedikt Wiens,&nbsp;Constantin A. Hintschich,&nbsp;Natascha Platz Batista da Silva,&nbsp;Katja Evert,&nbsp;Frank Haubner,&nbsp;Friedrich G. Kapp,&nbsp;Christina Wendl,&nbsp;Kathrin Renner,&nbsp;Christopher Bohr,&nbsp;Thomas Kühnel,&nbsp;Veronika Vielsmeier","doi":"10.1007/s10456-023-09896-3","DOIUrl":"10.1007/s10456-023-09896-3","url":null,"abstract":"<div><p>Extracranial arteriovenous malformations (AVMs) are regarded as rare diseases and are prone to complications such as pain, bleeding, relentless growth, and high volume of shunted blood. Due to the high vascular pressure endothelial cells of AVMs are exposed to mechanical stress. To control symptoms and lesion growth pharmacological treatment strategies are urgently needed in addition to surgery and interventional radiology. AVM cells were isolated from three patients and exposed to cyclic mechanical stretching for 24 h. Thalidomide and bevacizumab, both VEGF inhibitors, were tested for their ability to prevent the formation of circular networks and proliferation of CD31⁺ endothelial AVM cells. Furthermore, the effect of thalidomide and bevacizumab on stretched endothelial AVM cells was evaluated. In response to mechanical stress, VEGF gene and protein expression increased in patient AVM endothelial cells. Thalidomide and bevacizumab reduced endothelial AVM cell proliferation. Bevacizumab inhibited circular network formation of endothelial AVM cells and lowered VEGF gene and protein expression, even though the cells were exposed to mechanical stress. With promising in vitro results, bevacizumab was used to treat three patients with unresectable AVMs or to prevent regrowth after incomplete resection. Bevacizumab controlled bleeding, pulsation, and pain over the follow up of eight months with no patient-reported side effects. Overall, mechanical stress increases VEGF expression in the microenvironment of AVM cells. The monoclonal VEGF antibody bevacizumab alleviates this effect, prevents circular network formation and proliferation of AVM endothelial cells in vitro. The clinical application of bevacizumab in AVM treatment demonstrates effective symptom control with no side effects.</p><h3>Graphical abstract</h3><p>Mechanical stress increases VEGF expression in endothelial AVM cells, possibly causing the VEGF upregulation in the microenvironment of AVM cells. The resulting RAS/RAF/MEK/ERK signaling in leads to progression of fast-flow malformations. The monoclonal VEGF-A antibody bevacizumab alleviates this effect, prevents circular network formation and proliferation of AVM endothelial cells in vitro. Sporadically occurring slow-flow malformations (LMs, VMs) have mutations in <i>TEK</i> or <i>PIK3CA</i>. <i>TEK</i> encodes the endothelial receptor tyrosine kinase TIE2. Sporadic extracranial fast-flow malformations (AVMs) show mutations in <i>KRAS, BRAF</i> and <i>MAP2K1</i>, which encodes the dual specificity mitogen-activated protein kinase MEK1. Combined targeting of the molecular causes of the disease could be key to achieve symptom control and reduce lesion growth. Orange: gain-of-function; Blue, circled with orange: enhanced signaling.</p>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 1","pages":"91 - 103"},"PeriodicalIF":9.2,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive summary of the 14th HHT international scientific conference","authors":"Roxana Ola,&nbsp;Josefien Hessels,&nbsp;Adrienne Hammill,&nbsp;Cassi Friday,&nbsp;Marianne Clancy,&nbsp;Hanny Al-Samkari,&nbsp;Stryder Meadows,&nbsp;Vivek Iyer,&nbsp;Rosemary Akhurst","doi":"10.1007/s10456-023-09886-5","DOIUrl":"10.1007/s10456-023-09886-5","url":null,"abstract":"<div><p>Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by small, dilated clustered vessels (telangiectasias) and by larger visceral arteriovenous malformations (AVMs), which directly connect the feeding arteries with the draining veins. These lesions are fragile, prone to rupture, and lead to recurrent epistaxis and/or internal hemorrhage among other complications. Germline heterozygous loss-of-function (LOF) mutations in Bone Morphogenic Protein 9 (BMP9) and BMP10 signaling pathway genes (endoglin-<i>ENG</i>, activin like kinase 1 <i>ACVRL1</i> aka <i>ALK1,</i> and <i>SMAD4</i>) cause different subtypes of HHT (HHT1, HHT2 and HHT-juvenile polyposis (JP)) and have a worldwide combined incidence of about 1:5000. Expert clinicians and international scientists gathered in Cascais, Portugal from September 29th to October 2^nd, 2022 to present the latest scientific research in the HHT field and novel treatment strategies for people living with HHT. During the largest HHT scientific conference yet, participants included 293 in person and 46 virtually. An impressive 209 abstracts were accepted to the meeting and 59 were selected for oral presentations. The remaining 150 abstracts were presented during judged poster sessions. This review article summarizes the basic and clinical abstracts selected as oral presentations with their new observations and discoveries as well as surrounding discussion and debate. Two discussion-based workshops were also held during the conference, each focusing on mechanisms and clinical perspectives in either AVM formation and progression or current and future therapies for HHT. Our hope is that this paper will represent the current progress and the remaining unanswered questions surrounding HHT, in order to serve as an update for those within the field and an invitation to those scientists and clinicians as yet outside of the field of HHT.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"26 1","pages":"27 - 37"},"PeriodicalIF":9.8,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-023-09886-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A defined clathrin-mediated trafficking pathway regulates sFLT1/VEGFR1 secretion from endothelial cells","authors":"Karina Kinghorn,&nbsp;Amy Gill,&nbsp;Allison Marvin,&nbsp;Renee Li,&nbsp;Kaitlyn Quigley,&nbsp;Simcha Singh,&nbsp;Michaelanthony T. Gore,&nbsp;Ferdinand le Noble,&nbsp;Feilim Mac Gabhann,&nbsp;Victoria L. Bautch","doi":"10.1007/s10456-023-09893-6","DOIUrl":"10.1007/s10456-023-09893-6","url":null,"abstract":"<div><p>FLT1/VEGFR1 negatively regulates VEGF-A signaling and is required for proper vessel morphogenesis during vascular development and vessel homeostasis. Although a soluble isoform, sFLT1, is often mis-regulated in disease and aging, how sFLT1 is trafficked and secreted from endothelial cells is not well understood. Here we define requirements for constitutive sFLT1 trafficking and secretion in endothelial cells from the Golgi to the plasma membrane, and we show that sFLT1 secretion requires clathrin at or near the Golgi. Perturbations that affect sFLT1 trafficking blunted endothelial cell secretion and promoted intracellular mis-localization in cells and zebrafish embryos. siRNA-mediated depletion of specific trafficking components revealed requirements for RAB27A, VAMP3, and STX3 for post-Golgi vesicle trafficking and sFLT1 secretion, while STX6, ARF1, and AP1 were required at the Golgi. Live-imaging of temporally controlled sFLT1 release from the endoplasmic reticulum showed clathrin-dependent sFLT1 trafficking at the Golgi into secretory vesicles that then trafficked to the plasma membrane. Depletion of STX6 altered vessel sprouting in 3D, suggesting that endothelial cell sFLT1 secretion influences proper vessel sprouting. Thus, specific trafficking components provide a secretory path from the Golgi to the plasma membrane for sFLT1 in endothelial cells that utilizes a specialized clathrin-dependent intermediate, suggesting novel therapeutic targets.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"27 1","pages":"67 - 89"},"PeriodicalIF":9.2,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10258225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}